Ulldemolins Aznar Pablo, Muñoz Vicente Elia, Roselló-Sastre Esther
Universitat Jaume I, Castellón de la Plana, Castellón, España.
Servicio de Anatomía Patológica, Hospital General Universitari de Castellón, Castellón de la Plana, Castellón, España.
Rev Esp Patol. 2022 Apr-Jun;55(2):125-134. doi: 10.1016/j.patol.2021.11.002. Epub 2022 Feb 11.
The Paris System (PS) has replaced the classical Papanicolaou System (PapS) in reporting urine cytology, due to its improved sensitivity and negative predictive value (NPV) without loss of specificity. Furthermore, it has enabled the risk of malignancy to be established in each cytological category. The aim of this study is to compare the Paris System with previous results and determine the changes in sensitivity, specificity, positive predictive value, NPV and risk of malignancy in our centre, MATERIALS AND METHODS: Evaluation of the diagnostic power of urine cytology by means of a retrospective cohort study, comparing two series of 400 cytological studies, one using the Papanicolaou System and the other the Paris System.
In the detection of high-grade urothelial carcinoma, Paris System has better specificity (93.82% PapS vs 98.64% PS; P=.001) and PPV (39.5% PapS vs 70.6% PS; P=.044) than Papanicolaou System, without changes in sensitivity (53.5% PapS vs 37.5% PS; P=.299) or NPV (96.4% PapS vs 94.8% PS; P=.183). The risk of malignancy for the atypical category increases from low to high levels (1.6% PapS vs 40.0% PS; P=.001); the other categories showed no significant statistical changes.
The Paris System improves specificity and positive predictive value and establishes a better indication of risk of malignancy for each category, enabling specific clinical management in each case.
巴黎系统(PS)已在尿液细胞学报告中取代了经典的巴氏系统(PapS),因为它在不损失特异性的情况下提高了敏感性和阴性预测值(NPV)。此外,它还能在每个细胞学类别中确定恶性风险。本研究的目的是将巴黎系统与先前的结果进行比较,并确定我们中心在敏感性、特异性、阳性预测值、NPV和恶性风险方面的变化。
通过回顾性队列研究评估尿液细胞学的诊断能力,比较两个系列的400例细胞学研究,一个使用巴氏系统,另一个使用巴黎系统。
在检测高级别尿路上皮癌方面,巴黎系统比巴氏系统具有更好的特异性(巴氏系统为93.82%,巴黎系统为98.64%;P = 0.001)和阳性预测值(巴氏系统为39.5%,巴黎系统为70.6%;P = 0.044),而敏感性(巴氏系统为53.5%,巴黎系统为37.5%;P = 0.299)或NPV(巴氏系统为96.4%,巴黎系统为94.8%;P = 0.183)没有变化。非典型类别的恶性风险从低水平增加到高水平(巴氏系统为1.6%,巴黎系统为40.0%;P = 0.001);其他类别没有显著的统计学变化。
巴黎系统提高了特异性和阳性预测值,并为每个类别建立了更好的恶性风险指示,从而能够针对每个病例进行具体的临床管理。